Login
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp.

anteristech.com

What Do They Do?

Develops a transcatheter aortic valve system and supplies engineered tissue to medical-device companies for heart-valve procedures.

How Do They Make Money?

Customers buy regenerative tissue products directly, with sales occurring when goods are delivered; contracts typically have no significant unusual payment terms beyond 30 days.

FY2025 revenue

Who Are Their Customers?

Medical-device maker 4C buys ADAPT tissue for its devices, while distributor LeMaitre bought CardioCel and VascuCel products under a manufacturing and supply arrangement. The company describes its sales as direct product sales.

Do Revenues Turn Into Profits?

No. It lost $94.1M in FY2025.

Operating income, FY2025
−4860% of revenue
▼ −20% (Loss) vs FY2024 (−$78.4M, −2966%)
Net income, FY2025
−4873% of revenue
▼ −23% (Loss) vs FY2024 (−$76.3M, −2888%)
Free cash flow, FY2025
−4128% of revenue
▼ −26% (Loss) vs FY2024 (−$63.5M, −2404%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +21%
vs $429K in Q3 FY2025
Net income
▼ −21% (Loss)
vs −$22.2M in Q3 FY2025
  • Sep 4, 2026 Brent Moen appointed chief financial officer Matthew McDonnell left the CFO role to become Head of Australia.

Who Do They Compete With?

Competes with Edwards Lifesciences and Medtronic

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support